

OncoOne Establishes Scientific Advisory Board to Support OxMIF-targeted Anti-Cancer Drug Development Programs

Klosterneuburg, Austria – September 3, 2020 – [OncoOne](#) today announced the establishment of a Scientific Advisory Board to provide strategic, scientific and preclinical and clinical research guidance for OncoOne’s drug development programs based on targeting the oxidized macrophage migration inhibitory factor (oxMIF). OxMIF is an isoform of the macrophage migration inhibitory factor (MIF), generated by a post-translational mechanism and characterized by a remarkable tumor specificity, therefore representing an exciting new drug target in solid tumor indications. Members of the newly-formed Scientific Advisory Board include Michael Freissmuth, M.D., Dirk Jäger, M.D., and Florian Rüker, Ph.D.

“The formation of our Scientific Advisory Board achieves an important goal for our Company, enabling access to critical guidance from esteemed specialists in antibody engineering, preclinical and clinical development,” said Randolph Kerschbaumer, Ph.D., CEO of OncoOne. “Speaking for the entire OncoOne team, I am looking forward to harnessing their broad expertise as we seek to exploit the breadth of possibilities of oxMIF to target specific tumor indications through a range of drug modalities. Their support will help on our path toward clinical trials and our goal of providing innovative treatments for cancer indications with poor prognosis.”

The inaugural members of the OncoOne Scientific Advisory Board include:

Michael Freissmuth, M.D.

Dr. Freissmuth is the Director at the Centre of Physiology & Pharmacology as well as the Chairman of the Institute of Pharmacology at the Medical University in Vienna. He was appointed as Professor of Pharmacology in 1995 and has received many awards including the Novartis Award for Medicine. Dr. Freissmuth is a member of numerous editorial boards and serves on several review panels and Scientific Advisory Boards. His most recent appointments include positions in international panels such as the Scientific Advisory Board of the Institut Cochin de Génétique Moléculaire in Paris and of the Engelhorn Foundation for Life Sciences. He is also a member of the supervisory board of Boehringer Ingelheim Austria and chair of the reimbursement committee of the Association of Austrian Sickness Funds.

Dirk Jäger, M.D.

Dr. Jäger is Managing Director of the National Center for Tumor Diseases (NCT) Heidelberg and Medical Director of the Medical Oncology Department at Heidelberg University Hospital where he is responsible for the clinical research area representing all oncological departments. A main focus of his department is the translation of innovative treatment options into early clinical trials. Since 2005, Dr. Jäger is head of the research laboratory for tumor immunology at the NCT and focuses on cancer immunotherapy. He also leads the Clinical Cooperation Unit of Applied Tumor Immunity and has received the Investigator Award of the Cancer Research Institute in New York.

Florian Rümer, Ph.D.

Dr. Florian Rümer is Associate Professor, Deputy Head of the Department of Biotechnology and Head of the Institute of Molecular Biotechnology at the University of Natural Resources and Life Sciences, Vienna (BOKU), encompassing a team of more than 230. He is a co-founder of F-star and co-inventor of F-star's core Modular Antibody Technology, which allows to generate antigen binding sites in constant domains of immunoglobulins. Dr. Rümer serves F-star as Scientific Advisor. He also founded the Christian Doppler Laboratory (CD-Lab) for Antibody Engineering at BOKU where he acted as Co-head. Subsequently, he supported the establishment of the CD-Lab for Innovative Immunotherapeutics in collaboration with F-star and Merck KGaA, where he acts as Scientific Advisor.

About OncoOne

OncoOne seeks to overcome the limitations of targeting macrophage migration inhibitory factor by harnessing the high tumor-specificity of the disease-related isoform, oxidized macrophage migration inhibitory factor (oxMIF). The Company is focused on developing multiple proprietary drug modalities to leverage oxMIF's potential as a target for systemic treatment of pancreatic, colorectal, ovarian and lung cancer. Equipped with a successful track-record in early-stage drug development, as well as a deep understanding of the target itself, OncoOne's leadership will advance a pipeline based on oxMIF's promise in oncology, with the goal of expanding into other disease areas. www.oncoone.com

For OncoOne:

Randolf Kerschbaumer, Ph.D., CEO

Website: <http://www.oncoone.com/>

E-mail: office@oncoone.com

Phone: +43 1 909 2208 - 6000

For Media Inquiries:

Trophic Communications

Gretchen Schweitzer or Valeria Fisher

E-mail: schweitzer@trophic.eu or OncoOne@trophic.eu

Phone: +49 892 388 7735 or +49 172 861 8540